SunRegen Healthcare AG was recognized by JLABS of J&J

---

September 1, 2023

SunRegen JLABS recognition: SunRegen Healthcare AG was awarded a residency at JLABS@Shanghai. It is the third time SunRegen was recognized by pharma industry leader Johnson & Johnson. JLABS is a biopharmaceutical incubator set up by the pharmaceutical giant Johnson & Johnson, who uses the strictest standards to select innovative projects worldwide.

SunRegen@JLABS: https://jnjinnovation.com/JLABSNavigator/company/SunRegen_Healthcare_AG

SunRegen’s residency at JLABS@Shanghai gives the company access to advanced laboratory facilities. It also provides expert mentorship and opportunities to collaborate with other leading biotech innovators.

This recognition highlights SunRegen’s dedication to developing cutting-edge therapies in regenerative medicine. By participating in the JLABS program, SunRegen can accelerate its research, explore new therapeutic approaches, and strengthen global partnerships.

JLABS supported previous companies, which achieved significant breakthroughs. SunRegen aims to continue this tradition of innovation. The company will make meaningful contributions to the biotech industry and bring innovative solutions to patients worldwide.

The residency also reinforces SunRegen’s reputation as a pioneering force in healthcare innovation.